Company profileNeuroprosthetic
Cochlear
Maker of the Nucleus cochlear implant, the most widely used kind of neural prosthesis.
- Location
- Sydney, Australia
- Founded
- 1981
- Class
- NeuroprostheticHearing implants write sound to the auditory nerve. Nothing is decoded from the brain, so it is not counted as a BCI company.Not counted among core BCI companies.
- Also known as
- Cochlear Limited · Cochlear Ltd · Cochlear Americas · Cochlear Bone Anchored Solutions
- Website
- cochlear.com
- Funding stage
- Public
- Sources last checked
- 6 Oct 2026
What they are building
Sydney company founded in 1981 to bring to market the multichannel implant pioneered by Graeme Clark; the first commercial Nucleus implant was placed in 1982. It makes Nucleus cochlear implants, the Nucleus auditory brainstem implant, and Baha and Osia bone-conduction implants.
- Interface category
- Cochlear implants · Auditory brainstem implants
- Signal
- Cochlear: Electrical pulses along an array ordered by pitchABI: Electrical pulses across a paddle of disc electrodes
- Invasiveness
- Invasive
- Recording / stimulation
- Stimulation
- Main use cases
- Hear
Where they are clinically
Approved / cleared
Authorised by a regulator for a defined use. Always check the scope.
Cochlear implants are on the market and are routine care. The company's count of people helped covers its bone-conduction implants as well as its cochlear implants.
Access today
Available
Authorised and obtainable for a defined group of patients or users.
- Shown in people
- More than 700,000 people helped to hear with its implantable systems, by the company's own count, and 97 registered studies with a Cochlear company as lead sponsor.
- Still an aim
- Not a BCI aim: its development is in hearing.
- What stands in the way
- It writes and does not read: the implant delivers sound and takes nothing back from the nervous system.
On record here: 0 peer-reviewed papers
Why this company matters
Cochlear is the commercial benchmark for a neural interface. It took an implant from one surgeon's programme to hundreds of thousands of users, with the manufacturing, the clinic network and the lifelong support that takes. Implanted BCIs are at the start of that road. The comparison has a limit: the implant writes sound to the auditory nerve and reads nothing of what the listener intends.
Key milestones
IP and patents
Filings spread across 6 of the 11 layers, most often stimulation (13 of 13 families) and interface and electrodes (12).
- 13
- patent families identified and counted as BCI
- 2016
- earliest first filing among them
- 7
- first filed since 2021; the latest years are incomplete
- 6 of 13
- include a granted member, of those whose family record was read
Across the stack: families by layer
Themes, by number of families: stimulation (13), electrodes and arrays (12), wireless telemetry (7), signal processing (3), closed loop (3), peripheral interfaces (2). A family can carry several.
Published in: United States (8), China (6), Australia (2), Denmark (1), counted over the 13 families whose full record was read.
Representative families
- Methods and systems for determination of treatment therapeutic window, detection, prediction, and classification of neuroelectrical, cardiac, and/or pulmonary events, and optimization of treatment according to the samefirst filed 2020 · Electrodes and arrays, Signal processing, Neural decodingGranted · EP
- Implantable tinnitus therapyfirst filed 2020 · Electrodes and arrays, Implant electronics, StimulationGranted · US
- Improving musical perception of a recipient of an auditory devicefirst filed 2019 · Electrodes and arrays, Wireless telemetry, StimulationGranted · CN, US
- Near infrared light in hearing aid appliancesfirst filed 2018 · Electrodes and arrays, Optical interfaces, Wireless telemetryGranted · CN, EP, US
- Hearing prosthesis programmingfirst filed 2016 · Electrodes and arrays, StimulationGranted · CN, US
- Electrocochleography testing in hearing prosthesesfirst filed 2016 · StimulationGranted · US
7 more families counted, and 2 kept as adjacent neural technology
- Neural interface-based stimulation parametersfirst filed 2025 · Electrodes and arrays, Peripheral interfaces, Wireless telemetryApplication
- Furlable electrode arrayfirst filed 2024 · Electrodes and arrays, Packaging and hermeticity, Wireless telemetryApplication
- Interoperative measurementsfirst filed 2023 · Electrodes and arrays, Implant electronics, Wireless powerApplication
- Enhanced perception of target signalsfirst filed 2023 · Electrodes and arrays, Speech decoding, StimulationApplication
- Multimodal neurological monitoring systemfirst filed 2023 · Electrodes and arrays, Signal processing, StimulationApplication
- Synchronized spectral analysisfirst filed 2022 · Electrodes and arrays, Peripheral interfaces, Wireless telemetryApplication
- Phase coherence-based analysis of biological responsesfirst filed 2021 · Electrodes and arrays, Wireless telemetry, StimulationApplication
- Adaptive neural interface for an implantable medical devicefirst filed 2024 · Electrodes and arrays, Implant electronics, Stimulation · adjacent, not counted as BCIApplication
- Integrated implantable hearing device, microphone and power unitfirst filed 2005 · Wireless power, Wireless telemetry, Stimulation · adjacent, not counted as BCIStatus not yet checked
Families found for Cochlear in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this
Competitive context
Sources
- 01
Cochlear Limited (opens in a new tab)
Independent reportingWikipediaChecked against source 6 Oct 2026
An encyclopaedia entry, used for the company's history: founded 1981, first commercial Nucleus implant in 1982, listed on the Australian Securities Exchange in 1995, headquarters in Sydney.
- 02
About Cochlear (opens in a new tab)
Company reportedCochlearChecked against source 6 Oct 2026
The company's own count: more than 700,000 people helped to hear with its implantable systems, which it names as Nucleus, Baha and Osia.
- 03
ClinicalTrials.gov: studies with a Cochlear company as lead sponsor (opens in a new tab)
Clinical registryClinicalTrials.govChecked against source 6 Oct 2026
97 studies on 6 October 2026: 91 under Cochlear, 5 under Cochlear Bone Anchored Solutions and 1 under Cochlear, Asia Pacific.
- 04
Peer reviewedFrontiers in Neuroscience2019Checked against source 6 Oct 2026
A review. Used for the placement on the cochlear nucleus, the FDA approval of 2000 for neurofibromatosis type 2 from age 12, the Nucleus device, more than 1,000 implanted worldwide, typical outcomes, paediatric studies and the directions in development.